WO2013183062A3 - Palatable formulations of ibuprofen - Google Patents

Palatable formulations of ibuprofen Download PDF

Info

Publication number
WO2013183062A3
WO2013183062A3 PCT/IN2013/000344 IN2013000344W WO2013183062A3 WO 2013183062 A3 WO2013183062 A3 WO 2013183062A3 IN 2013000344 W IN2013000344 W IN 2013000344W WO 2013183062 A3 WO2013183062 A3 WO 2013183062A3
Authority
WO
WIPO (PCT)
Prior art keywords
ibuprofen
masked
taste
palatable
oral
Prior art date
Application number
PCT/IN2013/000344
Other languages
French (fr)
Other versions
WO2013183062A2 (en
Inventor
Pratibha Sudhir Pilgaonkar
Maharukh Tehmasp Rustomjee
Anilkumar Surendrakumar Gandhi
Original Assignee
Rubicon Research Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Research Private Limited filed Critical Rubicon Research Private Limited
Publication of WO2013183062A2 publication Critical patent/WO2013183062A2/en
Publication of WO2013183062A3 publication Critical patent/WO2013183062A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to oral palatable pharmaceutical formulations of ibuprofen. Taste-masked oral formulation of ibuprofen is provided wherein the disagreeable taste and the associated unpleasant throat burning sensation of ibuprofen is masked by coating with at least one lipophilic agent. The present invention also relates to providing oral palatable pharmaceutical compositions of such taste-masked ibuprofen in the form of orally disintegrating tablets, bite-dispersion tablets, granules, dispersible tablets, or the like. Further process for preparation of such taste-masked palatable formulations is also disclosed.
PCT/IN2013/000344 2012-06-05 2013-05-30 Palatable formulations of ibuprofen WO2013183062A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1648MU2012 2012-06-05
IN1648/MUM/2012 2012-06-05

Publications (2)

Publication Number Publication Date
WO2013183062A2 WO2013183062A2 (en) 2013-12-12
WO2013183062A3 true WO2013183062A3 (en) 2014-01-30

Family

ID=49712774

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000344 WO2013183062A2 (en) 2012-06-05 2013-05-30 Palatable formulations of ibuprofen

Country Status (1)

Country Link
WO (1) WO2013183062A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112762A1 (en) * 2014-06-10 2017-04-27 Capsugel Belgium Nv Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
US11324699B2 (en) 2014-12-04 2022-05-10 Capsugel Belgium Nv Lipid multiparticulate formulations
US11638698B2 (en) 2017-04-20 2023-05-02 Zeenar Enterprises Pty Ltd Liquid crystalline dosage form for administering a statin
WO2018191793A1 (en) * 2017-04-20 2018-10-25 Zeenar Enterprises Pty Ltd Fast disintegrating tablet
WO2019009927A1 (en) 2017-07-06 2019-01-10 Adorus Pharmaceuticals Llc Blend compositions for oral administration as a rapidly dissolving powder and/or suspension
CN108926530A (en) * 2018-08-17 2018-12-04 江苏科瑞达药业有限公司 A kind of paracetamol liquid preparation with efficient suspension effect
US20210361581A1 (en) * 2018-10-22 2021-11-25 Ioi Oleo Gmbh Additive for a powder material intended for compaction into shaped bodies
JP7376582B2 (en) * 2018-10-22 2023-11-08 イーオーイー オレオ ゲーエムベーハー Additive for powder materials for compression into compacts
TW202045153A (en) * 2019-02-22 2020-12-16 英商康泰倫特英國斯文敦載迪斯有限公司 Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
AU2020224375A1 (en) * 2019-02-22 2021-10-14 Catalent U.K. Swindon Zydis Limited Minimizing aeration of suspensions during in-line mixing
GB2585411B (en) 2019-02-22 2023-10-04 Catalent Uk Swindon Zydis Ltd Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension
GB2585413B (en) 2019-02-22 2023-04-26 Catalent Uk Swindon Zydis Ltd Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
KR102530032B1 (en) * 2019-09-18 2023-05-09 정원구 Drug suspension for companion animals and method for manufacturing the same
WO2022263505A1 (en) * 2021-06-16 2022-12-22 Société des Produits Nestlé S.A. Methods of solid phase wax coating of an active ingredient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109745A (en) * 1993-12-17 1995-10-11 爱诗爱诗制药株式会社 Ibuprofen-containing solid composition
US5891476A (en) * 1997-12-22 1999-04-06 Reo; Joe P. Tastemasked pharmaceutical system
US20070292508A1 (en) * 2006-06-05 2007-12-20 Balchem Corporation Orally disintegrating dosage forms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109745A (en) * 1993-12-17 1995-10-11 爱诗爱诗制药株式会社 Ibuprofen-containing solid composition
US5891476A (en) * 1997-12-22 1999-04-06 Reo; Joe P. Tastemasked pharmaceutical system
US20070292508A1 (en) * 2006-06-05 2007-12-20 Balchem Corporation Orally disintegrating dosage forms

Also Published As

Publication number Publication date
WO2013183062A2 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
WO2013183062A3 (en) Palatable formulations of ibuprofen
WO2015120110A3 (en) Novel pharmaceutical formulations
WO2012021715A3 (en) Stable formulations of linaclotide
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
MX2011007817A (en) Controlled release pharmaceutical or food formulation and process for its preparation.
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2010021607A3 (en) Pharmaceutical formulation
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
WO2011104652A3 (en) Veterinary compositions
WO2008093075A3 (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
TN2015000135A1 (en) Modified release formulations for oprozomib
WO2014100351A3 (en) 8'-hydroxy-dihydroergotamine compounds and compositions
WO2010046933A3 (en) Pharmaceutical compositions of taste-masked linezolid
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2009084036A3 (en) Composition for treatment of viral infections
WO2012058695A3 (en) Compositions of (-)-17-(cyclobutylmethyl) morphinan-3, 14-diol
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
WO2014144407A8 (en) Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13800994

Country of ref document: EP

Kind code of ref document: A2